GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » DeferredTaxAndRevenue

Solvonis Therapeutics (LSE:SVNS) DeferredTaxAndRevenue : £0.00 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Solvonis Therapeutics's current deferred tax and revenue for the quarter that ended in Sep. 2024 was £0.00 Mil.

Solvonis Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Solvonis Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics DeferredTaxAndRevenue Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial - - - - -

Solvonis Therapeutics Quarterly Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Solvonis Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Solvonis Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines